AR051998A1 - Agentes terapeuticos - Google Patents
Agentes terapeuticosInfo
- Publication number
- AR051998A1 AR051998A1 ARP050105291A ARP050105291A AR051998A1 AR 051998 A1 AR051998 A1 AR 051998A1 AR P050105291 A ARP050105291 A AR P050105291A AR P050105291 A ARP050105291 A AR P050105291A AR 051998 A1 AR051998 A1 AR 051998A1
- Authority
- AR
- Argentina
- Prior art keywords
- naphthyl
- ethyl
- salt
- therapeutic agents
- ethylamine salt
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- RTCUCQWIICFPOD-SECBINFHSA-N (1r)-1-naphthalen-1-ylethanamine Chemical class C1=CC=C2C([C@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-SECBINFHSA-N 0.000 abstract 1
- KHSYYLCXQKCYQX-VIFPVBQESA-N (1s)-1-naphthalen-2-ylethanamine Chemical class C1=CC=CC2=CC([C@@H](N)C)=CC=C21 KHSYYLCXQKCYQX-VIFPVBQESA-N 0.000 abstract 1
- PGZGQQFVPOZCAQ-UHFFFAOYSA-N 2-[2-(4-hydroxyphenyl)ethylsulfanyl]-3-[4-[2-(4-methylsulfonyloxyphenoxy)ethyl]phenyl]propanoic acid Chemical compound C1=CC(OS(=O)(=O)C)=CC=C1OCCC(C=C1)=CC=C1CC(C(O)=O)SCCC1=CC=C(O)C=C1 PGZGQQFVPOZCAQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una sal de cinconidina, una sal de ( R )-(+)-1-(1-naftil)etilamina y una sal de (S)-(-)-1-(2-naftil)etilamina del ácido (-)-2-{[2-(4- hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil]propanoico, procesos para su preparacion, su utilizacion en el tratamiento de afecciones clínicas que incluyen trastornos lipídicos (dislipidemias) ya sea asociados o no con la resistencia a la insulina y otras manifestaciones del síndrome metabolico, y composiciones farmacéuticas que los contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0427701.8A GB0427701D0 (en) | 2004-12-17 | 2004-12-17 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051998A1 true AR051998A1 (es) | 2007-02-21 |
Family
ID=34090253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105291A AR051998A1 (es) | 2004-12-17 | 2005-12-15 | Agentes terapeuticos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080090905A1 (es) |
| EP (1) | EP1828112A1 (es) |
| JP (1) | JP2008524187A (es) |
| CN (1) | CN101080385A (es) |
| AR (1) | AR051998A1 (es) |
| GB (1) | GB0427701D0 (es) |
| TW (1) | TW200640843A (es) |
| WO (1) | WO2006064232A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200955A (zh) * | 2010-10-30 | 2019-09-06 | 金戴克斯治疗学有限责任公司 | 四氢异-α酸衍生物、组合物及方法 |
| CN103912301B (zh) * | 2014-04-10 | 2016-08-17 | 西安博深煤矿安全科技有限公司 | 一种矿井换热装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-12-17 GB GBGB0427701.8A patent/GB0427701D0/en not_active Ceased
-
2005
- 2005-12-14 EP EP05818448A patent/EP1828112A1/en not_active Withdrawn
- 2005-12-14 WO PCT/GB2005/004829 patent/WO2006064232A1/en not_active Ceased
- 2005-12-14 JP JP2007546179A patent/JP2008524187A/ja active Pending
- 2005-12-14 US US11/793,291 patent/US20080090905A1/en not_active Abandoned
- 2005-12-14 CN CNA2005800430615A patent/CN101080385A/zh active Pending
- 2005-12-15 AR ARP050105291A patent/AR051998A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144946A patent/TW200640843A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101080385A (zh) | 2007-11-28 |
| TW200640843A (en) | 2006-12-01 |
| GB0427701D0 (en) | 2005-01-19 |
| EP1828112A1 (en) | 2007-09-05 |
| US20080090905A1 (en) | 2008-04-17 |
| WO2006064232A1 (en) | 2006-06-22 |
| JP2008524187A (ja) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Madreiter-Sokolowski et al. | Targeting mitochondria to counteract age-related cellular dysfunction | |
| ES2634562T3 (es) | Métodos y composiciones para tratar hiperuricemia y trastornos metabólicos asociados con hiperuricemia | |
| AR083679A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
| CL2012003009A1 (es) | Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct. | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| ES2537539T3 (es) | Composición oftálmica | |
| AR075204A1 (es) | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
| PL1937065T3 (pl) | Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo | |
| BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| AR075582A1 (es) | Compuestos de 4- isopropilfenilglucitol | |
| AR065798A1 (es) | Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| ATE549323T1 (de) | Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie | |
| BR112014027884A2 (pt) | combinações farmacêuticas para tratamento de distúrbios metabólicos | |
| AR029412A1 (es) | Forma cristalina | |
| BR112014009165A2 (pt) | sal e uso médico | |
| ECSP055985A (es) | Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis | |
| AR051998A1 (es) | Agentes terapeuticos | |
| UY28372A1 (es) | Agentes terapéuticos | |
| UY28367A1 (es) | Agentes terapéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |